金吾财讯 | 招银国际表示，MSCI中国医疗指数2026年初至今累计上涨5.0%，跑赢MSCI中国指数6.2%。医药行业近期明显回调（MSCI中国医疗指数1月15日至今累计下跌9%），特别是创新药板块回调幅度较大（恒生生物科技指数1月15日至今累计下跌13%）。该机构认为，此轮调整原因包括博弈层面行业短期缺乏催化剂，以及行业轮动导致资金流出医药板块。中国创新药资产出海BD持续超预期，MNC对于中国资产的购买范围从单个管线拓宽至平台合作，进一步体现了中国创新药的竞争力。该机构认为，中国的AI制药技术发展迅猛，将涌现一批优秀的创新企业。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.